• Getinge reiterated its 2026 net sales outlook of 3%-5% organic growth, excluding Surgical Perfusion.
• Longer-term target calls for more than 12% adjusted EPS CAGR over 2024-2028.
• Currency sensitivity flagged, with Getinge net long USD versus SEK and EUR; the US accounted for 40.5% of 2025 net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getinge AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.